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The MYC genes encode nuclear sequence specific–binding DNA-binding proteins that are pleiotropic regulators of
cellular function, and the c-MYC proto-oncogene is deregulated and/or mutated in most human cancers. Experimental
studies of MYC binding to the genome are not fully consistent. While many c-MYC recognition sites can be identified in
c-MYC responsive genes, other motif matches—even experimentally confirmed sites—are associated with genes
showing no c-MYC response. We have developed a computational model that integrates multiple sources of evidence
to predict which genes will bind and be regulated by MYC in vivo. First, a Bayesian network classifier is used to predict
those c-MYC recognition sites that are most likely to exhibit high-occupancy binding in chromatin immunoprecipitation
studies. This classifier incorporates genomic sequence, experimentally determined genomic chromatin acetylation
islands, and predicted methylation status from a computational model estimating the likelihood of genomic DNA
methylation. We find that the predictions from this classifier are also applicable to other transcription factors, such as
cAMP-response element-binding protein, whose binding sites are sensitive to DNA methylation. Second, the MYC
binding probability is combined with the gene expression profile data from nine independent microarray datasets in
multiple tissues. Finally, we may consider gene function annotations in Gene Ontology to predict the c-MYC targets. We
assess the performance of our prediction results by comparing them with the c-myc targets identified in the biomedical
literature. In total, we predict 460 likely c-MYC target genes in the human genome, of which 67 have been reported to
be both bound and regulated by MYC, 68 are bound by MYC, and another 80 are MYC-regulated. The approach thus
successfully identifies many known c-MYC targets and suggests many novel sites. Our findings suggest that to identify
c-MYC genomic targets, integration of different data sources helps to improve the accuracy.
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site binding and function. PLoS Comput Biol 3(4): e63. doi:10.1371/journal.pcbi.0030063
Introduction
MYC plays a critical role in regulating cell proliferation,
growth, apoptosis, and differentiation. Human malignancies
are often associated with aberration of the c-MYC gene [1–3].
The diversity of its functions has been attributed to c-MYC’s
ability to activate or repress the transcription of an extensive
array of target genes mediating a wide range of cellular
activities [4–6]. c-MYC’s actions are mediated by sequence-
speciﬁc binding of the c-MYC protein, dimerized with its
partner MAX, to DNA elements called E-boxes with the core
sequence motif 59-CACGTG-39 [7–9]. Binding of the MYC–
MAX heterodimer to a target gene can directly activate or
repress transcription, but many E-boxes do not bind MYC,
and in many experimentally conﬁrmed cases, MYC binding is
not associated with changes in gene expression. Identifying
functional MYC binding sites and target genes is a critical
step in understanding both the biological role and molecular
mechanism of MYC action.
mRNA expression studies have identiﬁed many target
genes activated or repressed by c-MYC in various animal
and human cells or cell lines. The number of experimentally
validated c-myc targets are expanding rapidly thanks to the
use of high throughput methods [10–13]. The recent studies
of Basso et al. [14] and Remondini et al. [15] suggest that the
potential list of c-MYC targets could be much larger than
what was previously anticipated. However, different exper-
imental and theoretical studies give quite different ﬁndings,
and much work remains to be done to deﬁne the complete set
of c-MYC targets.
Gene expression studies alone cannot discriminate be-
tween direct and indirect targets of c-MYC action, although
network-based inference of direct action has been proposed
[14]. Recently, chromatin immunoprecipitation (ChIP) and
whole genome scale analysis of methylation status have
emerged as new sources of relevant data for the analysis of
genomic regulatory elements.
Theoretical analysis complements and extends experimen-
tal study, and several researchers have attempted to predict c-
MYC target genes using computational methods. By searching
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using genomic sequence evolutionary conservation,
Schuldiner et al. [16] identiﬁed 12 putative targets, two of
which were conﬁrmed by subsequent experimental analysis.
Zeller et al. [17] built a database of c-Myc responsive genes
that have been reported in publications and supported by
multiple lines of evidence. They then identiﬁed seven out of
12 candidate genes in this database using phylogenetic
analysis, and they conﬁrmed six of these predictions using
ChIP. The use of evolutionary conservation is also supported
by Haggerty [18] who categorized c-MYC targets into two
classes: Class I, to which the majority of genes belong, has E-
boxes that are evolutionarily conserved; and Class II, which
includes genes with no region of homology at or ﬂanking the
genomic regions that exhibit MYC binding.
The promoter regions of c-MYC–regulated genes often
contain E-box sequences that bind MYC with high occupancy.
Li et al. [17] analyzed genomic binding sites for c-MYC in
Burkitt lymphoma cells and found a strong correlation
between MYC DNA binding and gene transcription, strength-
ening the view that high binding occupancy of a c-MYC site
near a gene’s promoter region is, to some extent, a sign of a c-
MYC target gene. However, this is not a hard and fast rule,
and many sites that bind MYC with high occupancy are not
associated with c-MYC target genes. Fernandez et al. [19]
performed a large-scale assay for genomic Myc binding sites
in vivo by quantitative ChIP. They found that promoter E-
boxes are distributed in two groups differing in MYC binding
occupancy. The strongest DNA-sequence characteristic of
high-afﬁnity/high-occupancy targets was location of the E-
box within a CpG island. This observation can be partially
explained by the fact that most CpG dinucleotides in the
mammalian genome are subject to cytosine methylation
[20,21], but the methylation of the CpG dinucleotide in the
consensus myc binding site sequence reduces the binding
afﬁnity of myc–max dimers for the target DNA [22,23].
Further, DNA methylation is often coupled to and associated
with histone methylation and the formation of heterochro-
matin [24]. Recent work by Ernesto [25] shows that target sites
are only recognized MYC by whether they are packaged in
chromatin bearing high H3 K4/K79 methylation and H3
acetylation. This is true for both classic E-box (CACGTG) and
alternative sequence sites.
With the abundant volumes of experimental data on c-MYC
target gene expression and in vivo binding of MYC to the
genome, there is an increasing need to integrate these
information resources and to classify c-MYC responsive genes
into direct and indirect targets. In this paper, we identiﬁed c-
MYC target genes using a computational approach that draws
on data from multiple sources including gene expression
proﬁling, gene annotations, ChIP, sequence conservation,
and sequence composition. First, we developed a computa-
tional model to predict the likelihood of CpG methylation.
Next, we developed a computational strategy to predict which
E-box sites were likely to be functional MYC binding sites.
Finally, the binding predictions were integrated with gene
expression and gene annotation data to identify direct and
indirect c-MYC target genes. The performance of these tools
was validated by comparison with multiple experimental
datasets. Our method is able to successfully predict the
occupancy of the binding sites as revealed by CHIP. Although
this computational method was speciﬁcally built on c-MYC
data, it also provides useful information on the binding of
cAMP-response element-binding protein (CREB) [26], anoth-
er transcription factor whose binding is sensitive to DNA
methylation. After further integration with gene expression
data from different tissues and datasets, and the Gene
Ontology (GO) annotations for c-MYC targets, we identiﬁed
460 likely c-MYC target genes. Of these genes, 215 have been
previously identiﬁed as MYC bound or regulated and 245 are
novel. Our study shows that integrating multiple data sources
improved the prediction speciﬁcity of MYC binding site
prediction. Similarly, using gene expression proﬁles from
several independent studies improved the sensitivity for
target gene prediction. Our analysis suggests that much of the
variation between microarray-based gene expression assays
may be due to limitations of the technology. In addition,
there appears to be a signiﬁcant tissue-speciﬁc component to
the responses of some c-MYC target genes.
Results
Computational Prediction of Genome CpG Islands and
Hypomethylation Regions
The performance of the ﬁfth-order Markov model for
genomic methylation status was tested using an independent
dataset from the Human Epigenome Project [27]. We found
that 86.4% of these unmethylated sites fell within our
predicted hypomethylation regions. In contrast, only 22%
of the hypermethylated CpG sites were within the predicted
hypomethylated regions (p , 2.2e 16). We applied this model
to predict the CpG islands and hypomethylation regions on
the human genome. On the human repeat masked genome
NCBI35, we found that 0.71% of the human genome
sequences were CpG islands and 1.07% of the genome
sequences were predicted to be hypomethylated regions,
with 82% of the CpG islands falling within hypomethylated
regions. As anticipated, promoter regions had much higher
percentages of CpG islands and hypomethylated regions than
the whole genome. Based on our prediction results, 43% of
the human genes had CpG islands and 46% of the genes had
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Author Summary
c-MYC is an important proto-oncogene that controls the expression
of many other genes, and MYC regulation is deranged in many
cancers. Identifying c-MYC target genes is one of the key steps to
understand both the biological role and molecular mechanism of c-
MYC action. Defining the complete list of c-MYC target genes and
categorizing them as genes that are directly and indirectly
modulated remains a challenge. Computational models also help
us to understand the mechanisms modulating c-MYC function. We
describe a method to predict where MYC will bind in the genome
and which c-MYC binding sites will be biologically active. The
method integrates multiple sources of data, including both genome
sequence and functional annotations, to predict that 460 genes are
direct c-MYC targets. These include many genes previously known to
be c-MYC targets as well as 245 novel direct c-MYC targets. Using
multiple, independent gene-expression datasets improves the
sensitivity and specificity of the prediction and demonstrates
significant tissue-specific variation in c-MYC action at different
genes. Our study suggests that chromatin state plays an important
role in modulating both c-MYC binding-site activity and the
functional consequences of c-MYC binding.
MYC Response Element Modelhypomethylated regions within 5 Kb upstream of their
transcription start sites. In the 5 Kb upstream of the
transcription start sites, 4.4% of the sequence was covered
by a CpG islands and 6.7% of sequences were predicted to be
hypomethylated.
Computational Prediction of High Occupancy MYC
Binding Sites
In this step we identiﬁed sites in the human genome where
MYC is expected to bind in vivo with high occupancy.
Candidate MYC binding sites were identiﬁed by scanning the
complete human genome sequencing using the TRANSFAC
MATCH algorithm [28] and the MYC–MAX position speciﬁc
weight matrix (PSWM) MA0059 [29] from the JASPAR
database [30,31]. Sites that achieved a matrix score of 0.8
are referred to as motif matches. Four additional sources of
data were used to deﬁne a subset of these motif matches that
are likely to bind MYC in vivo: proximity to transcription
start sites, proximity to CpG islands, predicted hypomethy-
lation, and evolutionary conservation.
To train our algorithm, we began with the Fernandez et al.
[19] data for genomic Myc binding sites in live human cells.
This study examined MYC binding to more than 700 E-box
sequences in vivo by quantitative ChIP. The authors found
that promoter E-boxes were distributed in two groups that
bound MYC at distinct frequencies. In the Fernandez et al.
dataset, we only used sites where the PCR primers and the
associated E-box could be mapped back to the human
genome as an exact sequence match. Further, sites were
excluded when the dataset contained multiple contradictory
assay results. This ﬁltering process resulted in a set of 493
binding sites where ChIP was measured in either U937 or
HL60 cell lines (for 40% of the sites, data is available and
consistent across both cell lines). A high quality training
dataset was deﬁned using sites where ChIP results were
consistent across more than one assay. The training set had 43
nonredundant high-occupancy sites and 90 nonredundant
low-occupancy sites.
Using a Bayesian network classiﬁer, we integrated this high
quality training subset of the ChIP dataset with our
hypomethylation analysis and genomic sequence conserva-
tion data. The resulting classiﬁer predicts which sites in the
genome are likely binding MYC with high occupancy. In the
training process, we looked for the most important factors
determining MYC binding to DNA. The Kolmogorov–
Smirnov test showed that the following factors differed
signiﬁcantly (p , 0.01) between the high- and low-occupancy
sites: distance to transcription start site (Figure 1A), distance
to nearest CpG island (Figure 1B), distance to nearest
hypomethylation region (Figure 1C), phastCons scores [32]
(Figure 1D), and distance to nearest chromatin acetylation
island (Figure 1E). The CpG islands and hypomethylation
regions near or overlapping with the above MYC binding sites
were predicted with our Fast Motif Analyzer (FMA), described
in the Materials and Methods section. The acetylation island
information was derived from the Roh et al. high-resolution
genome-wide mapping of Lys 9 and Lys 14 diacetyl histone
H3 in resting and activated human T cells [33]. PhastCons
scores identify evolutionarily conserved elements using a
multiple alignment of genomic sequence weighted using a
phylogenetic tree. The PhastCons score is a base-by-base
conservation score that can be interpreted as the probability
that each base is in a conserved sequence element [32]. This
score is chosen as a measurement of sequence conservation
over other alternatives because it is available through the
widely used University of California Santa Cruz Genome
Browser, and could be readily incorporated into our model.
Using these datasets and a supervised classiﬁcation
approach [34], we evaluated several algorithms for the
prediction of high-occupancy MYC binding sites. The best
classiﬁcation results were obtained using a Bayesian network
classiﬁer (see Materials and Methods). This method assigned a
probability for every site in the genome. We predicted a site
to have high binding if this probability was above 0.5. The
Bayesian network shown in Figure 2 gave the best results on
the high-quality training dataset. A 10-fold cross-validation
showed a precision of 0.88 and a recall of 0.98 on the high-
occupancy binding sites prediction. When we applied this
classiﬁer to Fernandez’s entire dataset, it correctly identiﬁed
130 of the 183 high-occupancy sites and 258 of the 310 low-
occupancy sites.
To further verify that our algorithm was able to predict
high-occupancy MYC binding sites, we evaluated perfor-
mance of independently obtained test data. We considered
binding sites within 63 Kb of transcription start sites,
because almost all of the sites in the training data are within
this region. We used the MYC–MAX matrix MA0059 [29]
from the JASPAR database [30] to identify putative MYC
binding sites, and we applied the rules described above to sort
these sites into groups predicted to bind MYC with high and
low occupancy. Using TRANSFAC MATCH to analyze the
complete human genome sequence, we identiﬁed 89,560 MYC
sites within 63 Kb of a transcription start site for 14,387
genes. From these candidate sites, our method classiﬁed
14,638 sites in 5,276 genes as likely to bind MYC with high
occupancy.
We assessed the reliability of these predictions by compar-
ing them with two independently published experimental
datasets. One dataset is from Zeller et al. [35] using ChIP–PET
to map genomic c-MYC binding sites in human B cells. This
study the identiﬁed loci as PET sequence tag clusters with
varying numbers of tags per cluster. More tags matching a
cluster increases the reliability of binding site identiﬁcation.
Zeller’s paper deﬁned 964 PET-2þ clusters with two or more
tags per cluster falling within 3 kb of a TSS. PET-2þ may
contain a signiﬁcant number of false positive identiﬁcations.
Zeller et al. also deﬁned 113 PET-3þ cluster with three or
more tags per cluster and within 3 kb of a TSS. These are
believed to be highly reliable identiﬁcations. For the second
evaluation dataset, we used high-density oligonucleotide
array ChIP–chip data from Cawley et al. [36]. Looking only
at Chromosomes 21 and 22, Cawley et al. deﬁned 181 high-
occupancy MYC binding segments within 3 kb of a TSS.
In the experimental datasets, MYC binding is localized to a
segment of genome, but not necessarily a single E-box. We
refer to these segments as ‘‘MYC binding loci’’ and compare
these with our predictions at the gene level. Most of the
experimentally deﬁned MYC binding loci are associated with
a single gene. Table 1 compares the experimentally deﬁned
MYC binding loci that are within 3 Kb of a transcription start
site with those that were predicted by our methods. First, it is
apparent that the different experimental assays yield mark-
edly different results. Only one of the 113 Zeller PET-3þ loci
was also scored as a high-occupancy binding site by
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MYC Response Element ModelFigure 1. Distribution of Sequence Attributes
Distribution of sequence attributes used as input for the Bayesian classification.
(A) Distribution of distances to transcription start site.
(B) Distribution of distances to nearest CpG islands.
(C) Distribution of distances to nearest hypomethylation region.
(D) Distribution of PhastCons scores from the UCSC genome database.
(E) Distribution of distances to nearest chromatin acetylation island.
Sequence distance is shown in base pairs. All of the distances were natural log transformed.
doi:10.1371/journal.pcbi.0030063.g001
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MYC Response Element ModelFernandez et al. Similarly, only one of six Zeller PET-3þ loci
on Chromosomes 21 and 22 was identiﬁed as a high-
occupancy site by Cawley et al., and only four of the 181
binding loci identiﬁed by Cawley et al. were scored as high
occupancy in the Fernandez dataset. Comparing our pre-
dictions with the experimental datasets, we see higher levels
of agreement than the experimental datasets show among
themselves. This is in part a consequence of the fact that our
method predicted a larger number of loci (5,276) than are
observed in the experimental datasets. Interestingly, the
fractional overlap between our predictions and the Zeller et
al. dataset increases as we consider more conﬁdent clusters.
Whereas only about a quarter of the PET-2þ clusters contain
a predicted high-occupancy site, half of the PET-3þ cluster
and all of the PET-4þ clusters do. One-third of the loci
identiﬁed by Cawley et al. on Chromosomes 21 and 22
contain a site predicted to bind MYC with high occupancy,
and more than a quarter of our predicted high-occupancy
sites on these chromosomes are conﬁrmed by Cawley et al.
To extend the analysis to more tissues and cell types, we
used data from the MYC Target Gene Database. We
compared predictions for genes annotated as c-MYC targets
with predictions for a collection of genes selected at random
from the human genome. The MYC Target Gene Database
[17] includes more than 1,000 putative MYC target genes
reported to be either regulated or bound by Myc. These MYC
target genes tend to have more MYC recognition sites than do
randomly selected genes. Table 2 shows the performance of
our algorithm in the prediction of high-occupancy binding
sites. Each gene in Table 2 contains at least one putative MYC
site predicted by a motif match. The MYC target genes are
compared with a set of 1,000 randomly selected genes
containing 6,259 MYC sites, which served as the control
group. Second, we chose 589 genes showing myc binding from
the MYC Target Gene Database that were not in Fernandez’s
dataset. Third, we chose 417 genes showing Myc regulation
for which no binding data was available. The fourth set
consisted of 98 genes in MYC Target Gene Database showing
both myc binding and myc regulation that were not in
Fernandez’s dataset. For each group of genes, we used our
algorithm to predict the occupancy of each MYC recognition
site. Statistical signiﬁcance was assessed using Fisher’s exact
test on each test group against the control group. We found
that each of the putative c-MYC target groups had a
signiﬁcantly higher percentage of high-occupancy binding
sites than the genes in the randomly selected group. This
demonstrates that our algorithm is able to discriminate
biologically functional high-occupancy sites from low-occu-
pancy, presumably nonfunctional binding-site motif matches.
We next asked what genes were associated with the high-
occupancy binding sites. Many genes have multiple MYC
binding sites, but little information is available on how
multiple MYC sites affect each other’s binding. Therefore, in
our study we treated all the genes having high-occupancy
binding sites as potential MYC binding genes. Table 3 shows
the result of these predictions. The results show that known c-
MYC targets were predicted to bind MYC with a signiﬁcantly
higher frequency than random genes do. Thus, our method
has signiﬁcantly higher accuracy in discriminating the MYC
binding genes than does motif match alone.
Although our method was built using c-MYC data, the
attributes used in the model are general, so we anticipated
that the method might also be informative for other
Figure 2. Bayesian Network Classifier
Topology of the Bayesian network classifier for high-occupancy MYC
binding obtained by training. The detailed parameters for the model are
provided in Figure S2.
doi:10.1371/journal.pcbi.0030063.g002
Table 1. Comparison of Predicted MYC Binding Loci with Published Experimental Datasets
Dataset Cawley
(Chromosomes 21 and 22)
Zeller
(PET-2þ)
Zeller
(PET-3þ)
Zeller
(PET-4þ)
Fernandez Our Prediction
Cawley
(Chromosome 21 and 22)
181
a 7
a 1
a 0
a 4
a 58
a
Zeller (PET-2þ) 964 (45
a) 113 (6
a)9 ( 2
a)1 0 2 6 2
Zeller (PET-3þ) 113 (6
a)9 ( 2
a)1 5 6
Zeller (PET-4þ) 9( 2
a )0 9
Fernandez 183 (10
a)1 3 0
b
Our prediction 5,276 (204
a)
aNumber of loci on Chromosomes 21 and 22 in corresponding dataset.
bFernandez dataset is used for training our model, so this is not an independent assessment.
doi:10.1371/journal.pcbi.0030063.t001
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MYC Response Element Modeltranscription factors that are sensitive to DNA methylation.
CREB has a CpG dinucleotide in its binding sequence and its
binding is sensitive to DNA methylation. We applied our
method to the analysis of CREB sites and compared our
predictions with a previous ChIP–chip study [26] of 10,209
distinct promoters on the human genome that were
predicted to have at least one cAMP-responsive element
deﬁned as a match to a simple cAMP-responsive element
consensus-site algorithm. Forty of these sites were conﬁrmed
by manual ChIP assays. Applying our model to these 40 genes,
we correctly classiﬁed 21 of the 23 high CREB occupancy
genes with seven false positives (Table 4). The ChIP–chip
assay identiﬁed 2,195 CREB high-occupancy binding sites
near promoters. Our model correctly classiﬁed 1,713 (78%) of
these high-occupancy promoters and gave 3,621 false
positives (Table 5). However, many false positives could
actually be true positives, because Zhang et al. pointed out in
their paper that, although their ChIP–chip method had a high
speciﬁcity, only 54% of the promoters occupied by CREB in
their manual ChIP assay showed positive in their ChIP–chip
assay. These predictions on CREB show that our method is
useful for the analysis of other transcription factors that are
sensitive to epigenetic factors.
Gene Expression Analysis
Myc binding does not always imply c-MYC regulation, and a
great deal remains to be learned about how the cell
determines which genes are actually regulated by c-MYC
under different conditions and in different tissues. To
address this issue, we analyzed the co-expression pattern of
genomic genes and c-MYC genes in two tissues where c-MYC
is reported to play an important biological role: B cell
lymphoma and prostate cancer.
The c-MYC gene is often deregulated in cancer and induces
the expression of many c-MYC target genes. Notable
examples include B cell lymphoma and prostate cancers.
We selected two datasets for analysis, a human B cell dataset
[14] of 336 samples and a human prostate cancer dataset [37]
of 102 samples based on number of samples in the dataset,
availability of the raw data, and thus use of a standard gene
expression analysis platform, the Affymetrix HG-U95Av2
microarray. The raw data for both datasets were reprocessed
with Bioconductor [38] and the RMA algorithm [39]. Figure 3
shows the RMA normalized log transformed expression
signals of the three c-myc probe sets on the HG-U95Av2
GeneChip for each dataset. In this study we used two c-myc
probe sets, ‘‘1973 s at’’ and ‘‘37724 at’’, because their
expression signals demonstrated a strong and consistent
correlation, whereas ‘‘1827 s at’’ was not strongly correlated
with either of the other two (see Figure 3). The Pearson’s
correlation coefﬁcients between each c-myc probe set and
every other probe set on the chip was calculated, and this
value is referred to as the co-expression pattern of c-myc with
the other genes. Figure 4 shows the distribution of these co-
expression patterns for data derived from B cells and prostate
cancers. Overall, 1,217 and 1,418 genes were found to be
signiﬁcantly correlated with c-MYC expression (FDR , 0.01)
in B cells and prostate cells, respectively. Altogether, 2,233
genes were highly correlated with c-MYC in these two
datasets; 403 genes were correlated with c-MYC expression
in both datasets. Table S1 lists the MYC correlated genes
identiﬁed in these two tissues.
Gene Function Annotation
Many known MYC target genes have functions involved in
cell cycle progression, apoptosis, and cellular transformation;
it is reasonable to hypothesize that unknown MYC targets will
share many of these functions. We constructed a set of gene
functions that were overrepresented in known MYC targets as
represented in GO terms. Using the experimentally veriﬁed
Table 3. Performance on MYC Binding Gene Predictions
Test Dataset Motif Matches Prediction Our Prediction Fisher Exact Test
1,000 random genes 478 (48%) 146 (15%) Control
755 genes (not in Fernandez’s datasets) showing MYC binding 589 (78%) 374 (50%) p , 1.3e-10
494 genes (not in Fernandez’s datasets) showing MYC regulation 417 (84%) 225 (46%) p , 6.2e-06
130 genes (not in Fernandez’s datasets) showing MYC binding and regulation 98 (75%) 68 (52%) p , 1.3e-05
doi:10.1371/journal.pcbi.0030063.t003
Table 2. Performance on MYC High-Occupancy Sites Prediction
Test Dataset (All the Genes Have at Least
One Motif That Matches Predicted MYC Site)
Predicted
Low Sites
Predicted
High Sites
Fisher
Exact Test
6,259 MYC sites on 1,000 random genes 5,361 (86%) 898 (14%) Control
3,323 MYC sites on 589 MYC binding genes, but not in Fernandez’s datasets 2,271 (68%) 1,052 (32%) p , 2.2e-16
2,673 MYC sites on 417 genes showing MYC regulation and without binding data,
but not in Fernandez’s datasets
1,979 (74%) 694 (26%) p , 2.2e-16
648 MYC sites on 98 genes showing binding and regulation by MYC, but not in
Fernandez’s datasets
406 (63%) 242 (37%) p , 2.2e-16
doi:10.1371/journal.pcbi.0030063.t002
PLoS Computational Biology | www.ploscompbiol.org April 2007 | Volume 3 | Issue 4 | e63 0607
MYC Response Element ModelMYC targets in the MYC target database [17] and considering
only the genes on the HG-U95Av2 chip, we found 144 known
MYC targets to which 875 terms in the Molecular Function and
Biological Process categories were applied. Because some GO
terms are too general to be as informative, in subsequent
analysis we only used the GO terms with fewer than 500
genes. Applying a hypergeometric test, we found 156 GO
terms overrepresented in the MYC target gene sets (p-value ,
0.025; Table S2). Among the top overrepresented GO terms
are those related to cell cycle, biosynthesis, nucleic acid
binding, and translational regulation. These ﬁndings corre-
late well with expectations based on the biology of c-MYC.
Integrated Approach for Predicting MYC Target Genes
Using the predicted MYC high-occupancy binding sites, the
c-MYC co-expressed genes in B cells and prostate cells, and
genes annotated with GO terms that are overrepresented in
known c-MYC targets, we applied a rule-based procedure to
deﬁne likely c-MYC targets. For a gene to be labeled as a c-
MYC target, it must meet four criteria. First, the gene must
have at least one MYC high-occupancy binding site. Second,
the signal variance of the gene’s probe set must be greater
than the mean variance across all probe sets in either the B
cell or prostate cancer dataset. Third, the correlation
coefﬁcient must be greater than zero and the signiﬁcance
of gene’s co-expression with c-MYC must be less than 0.01 in
either the B cell or prostate cancer dataset. Fourth, the GO
annotation for this gene must have at least one over-
represented c-MYC target-related GO term.
Applying these rules, we found 440 genes that meet our
criteria (see Table S3). Comparing our ﬁndings with the Myc
Target Gene Database [17], we found that in the literature,
128 of the predicted target genes are reported to bind MYC
and 142 are reported to be regulated by MYC. This represents
an independent validation of our ﬁndings because data from
the MYC Target Gene Database was not included in our
training data. Sixty-two of the predicted target genes were
reported to be both bound and regulated by MYC; we
successfully predicted 62 out of the 144 known MYC targets
on HG-U95Av2 platform.
Among the predicted genes, 264 were correlated with MYC
expression in B cells, 277 were correlated with MYC
expression in prostate cancers, and 101 were correlated in
both datasets. This high level of correlation further validates
our predictions. Among the 62 previously identiﬁed targets,
42 correlate with MYC expression in the B cell dataset, 39 in
the prostate dataset, and 19 in both. These ﬁndings show that
many MYC targets exhibit some tissue speciﬁcity in MYC
responsiveness. Figure 5 also shows that many of the known
MYC targets in the MYC Target Gene Database [17] have
different correlations of gene expression with MYC expres-
sion in the two tissues.
To further investigate c-MYC tissue speciﬁc responses, we
examined seven additional microarray gene expression data-
sets from breast, lung, prostate, and leukemia cancers (Table
6). All these datasets used the Affymetrix HG-U95Av2
platform. Adding correlation of gene expression with c-
MYC in these datasets, we were able to identify 20 additional
MYC targets. In total, 460 c-MYC target genes were predicted
including 215 in the MYC Target Gene Database that had
previously been reported to be bound or regulated by MYC
(Table S3); 144 were regulated by MYC and 132 were bound
by MYC. Further, we found evidence in the literature to
validate three additional MYC target gene predictions, ATF3
[40], HSP90A [41], and BAT1 [42]. Overall, 218 of our 460
predictions were validated, including 67 genes that have
evidences for both binding and regulation. We believe that
this is an underestimate for the true number of MYC targets
because we only considered the 8,000 GO annotated genes on
Affymetrix HG U95Av2 platform; this is slightly more than
one-third of the genes in the human genome.
We compared our predicted 460 genes from nine datasets
with the 2,063 genes in the MYC subnetwork predicted by
Basso et al. [14] and the 668 high-quality MYC direct
responsive genes identiﬁed by Zeller et al. [35]. Figure 6
shows the overlaps between these datasets. We see that the
overlap number is higher than would be expected purely by
chance, but well below complete agreement. Comparing these
datasets with the genes in the MYC Target Gene Database
(Table 7), we ﬁnd that our method shows a better speciﬁcity
Table 4. Prediction of CREB Occupancy in Genes Manually Assayed by ChIP
Prediction High Occupancy in Assay Low Occupancy in Assay Fisher Exact Test
Classified as high 21 7 p-Value , 0.033
Classified as low 2 5
doi:10.1371/journal.pcbi.0030063.t004
Table 5. Prediction of CREB Occupancy in Promoters Assayed by ChIP–chip
Prediction High Occupancy in Assay Low Occupancy in Assay Fisher Exact Test
Classified as high 1,713 3,621 p-Value , 2.2e-16
Classified as low 482 4,393
doi:10.1371/journal.pcbi.0030063.t005
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MYC Response Element Modelthan the other two approaches, even without applying GO
ﬁltering. Using the GO functional annotation improved the
speciﬁcity. We investigated the 45 targets identiﬁed by Basso
et al. that were missed in our 460 predicted targets.
Experimentally, these targets exhibit both binding and
regulation. Thirteen targets were missed due to their
relatively low expression variation or nonpositive correlation
with c-MYC across samples, six targets did not have any c-
MYC binding motif within 3 Kb of their transcription start
sites, 15 targets were false negatives in high-occupancy sites
prediction, and the other 11 targets did not have over-
represented GO terms.
Discussion
Using a Bayesian model, we integrate genome sequence
data and epigenetic information to identify myc recognition
sites in the human genome likely to bind c-MYC with high
occupancy. By combining the myc binding probability, gene
co-expression data, and functional annotations, we predicted
460 c-MYC targets among the genes presented on Affymetrix
HG-U95Av2 platform. The list of predicted c-MYC targets
contains many genes found previously in the literature, but
also 245 genes not previously identiﬁed as c-MYC targets. Our
method only predicts upregulated c-MYC targets because
downregulated c-MYC targets are not generally mediated by
E-box binding. Among the 67 predicted genes that have
already been observed to be bound and regulated by MYC, 61
are upregulated by MYC, ﬁve genes are reported to be
downregulated, and one has evidence for both downregula-
tion and upregulation. Thus, the predicted MYC targets agree
well with previous observations. In addition to these 67
independently validated predictions, we also identify 148
genes in the MYC Target Database, 68 of which are bound by
MYC in vivo and 80 of which are MYC regulated (Table 6).
Among the 250 predicted novel targets, 27 correspond to
MYC binding loci reported by Zeller et al. [35] and 11 of these
correspond to highly reliable binding loci with PET-3þ
clusters.
Different from previous studies predicting c-myc targets,
our study integrated four sources of data (genomic sequence,
gene expression, ChIP, and functional annotation) to
improve the speciﬁcity of predictions. Tools such as TRANS-
FAC or MatInspector, which rely on motif matches alone to
predict myc binding, have very high false positive rates. The
improved speciﬁcity obtained by our integrated approach
emphasizes the importance of epigenetic factors in modulat-
ing c-MYC binding to DNA. Although epigenetic status does
vary with tissue type and other factors, recent high
throughput studies show that tissue-speciﬁc variation in
genomic methylation is limited [27]. Adding genomic
acetylation islands data obtained on T cells to the model
improved the prediction precision from 0.81 to 0.88 and the
recall from 0.88 to 0.98 in cross-validation. Among the
attributes considered in the model, we found that the
distance to the nearest hypomethylation region is the most
informative; this attribute alone could correctly identify 80%
of the high- and low-occupancy sites in the cross validation.
However, adding the additional attributes does improve
performance, and considering all ﬁve attributes allows the
model to correctly identify 95% of all the cases in cross-
validation.
MYC is not the only transcriptional factor whose binding is
sensitive to the epigenetic factors such as DNA methylation
or chromatin acetylation. Because the attributes used in our
model are general and the epigenetic factors could inﬂuence
DNA binding through similar mechanisms, elements of our
model may also be useful for other transcription factors. As a
validation we applied our MYC binding prediction model to
another transcription factor, CREB [26]. Like MYC, the CREB
consensus binding sequence has a CpG dinucleotide and
CREB binding is sensitive to DNA methylation. Our analysis
shows that although our model was speciﬁcally built for the
study of c-MYC, it is still able to correctly discriminate most
of the high-occupancy binding sites and the majority of low-
occupancy binding sites. Thus, our approach to modeling
chromatin structure effects is transferable to other tran-
scription factors. ChIP–chip technology can partially address
the question of where transcription factors bind the genome,
but with current technology the resolution of TF binding loci
is limited and the data are error-prone. In addition,
computational modeling can help to understand the complex
transcriptional machinery. For example, adding or removing
an attribute to the model and assessing the affects on
performance is one way to evaluate the importance of this
attribute on the regulation of the DNA binding by a
transcription factor.
Combining different types of data offsets the shortcoming
of each. Obviously, our predictions based on genome
sequence alone cannot address tissue speciﬁc binding.
However, by taking gene expression data of speciﬁc tissues
into consideration, we restrict our identiﬁed targets to those
functionally regulated by MYC in the context of certain
tissues, which would be of real interest to the biological
community. In addition, integration of different types of data
Figure 3. c-MYC Expression Level in Both Tissues
The RMA normalized signal intensity of c-MYC probe sets in B cells
(upper) and prostates (lower). Green, c-MYC probe set ‘‘1827 s at’’; red,
c-MYC probe set ‘‘1973 s at’’; blue, c-MYC probe set ‘‘37724 at.’’
doi:10.1371/journal.pcbi.0030063.g003
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MYC Response Element ModelFigure 4. Distribution of c-MYC Co-Expression Coefficients in B cells and in Prostate Cancers
Distribution of correlation coefficients for c-MYC with genes in B cells (A) and prostate cancers (B). The predicted genes in Figure 4 refer to the high-
occupancy MYC binding and MYC target gene predictions.
doi:10.1371/journal.pcbi.0030063.g004
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MYC Response Element Modelalso allows us to predict which DNA–protein binding sites are
likely to trigger transcriptional regulation. Figure 4 shows
that compared with the expression of all genes, a higher
portion of genes from our MYC binding and function
predictions are highly correlated with c-MYC expression.
This demonstrates that our binding prediction and gene
function analysis do identify bona ﬁde c-MYC targets and are
helpful in improving the speciﬁcity of prediction.
One of the limitations in our target gene analysis is that we
only consider genomic sequences within 3 Kb of tran-
scription start sites. This was done because almost all of the
sites in our training data fall within this region, but there are
some high-occupancy MYC target sites far from any known
transcription start sites. It is possible that there are direct c-
MYC targets where the only functional MYC sites are more
than 3 Kb from the transcription start site. Increasing the
search window for c-MYC recognition sites might improve the
sensitivity of prediction, but such a change would also
decrease speciﬁcity.
Another limitation of our method is that we only consider
E-box–dependent MYC binding and regulation; MYC targets
regulated through other mechanisms will not be identiﬁed.
Transcriptional inhibition of MYC targets is often mediated
by mechanisms unrelated to E-box binding [43–47]. There-
fore, we only consider the MYC activation in our predictions
and consider only the expression of target genes that is
positively correlated with c-MYC expression. We do observe a
minority of genes where there is a signiﬁcant anti-correlation
of gene expression with c-MYC expression. The analysis of
these cases will be the subject of future work.
Distinguishing between direct and indirect targets of MYC
is an important issue. In the co-expression analysis we found
Figure 5. Expression of Known c-MYC Targets in Both Tissues
Pearson’s correlation coefficient of MYC target genes in B cells and
prostate cancers. The MYC target genes were from MYC Target Gene
Database.
doi:10.1371/journal.pcbi.0030063.g005
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MYC Response Element Modela large number of genes where expression levels showed
positive correlations with c-MYC expression and yet lacked a
high-occupancy MYC binding site, either predicted or
experimental. We believe that many of the genes are not
the direct targets of MYC, but it is difﬁcult to exclude the
possibility that they contain a functional MYC binding site
not detected by our own or experimental methods.
MYC responses vary signiﬁcantly between different tissues.
Less than half of our predicted MYC targets show signiﬁcant
gene expression correlation with c-MYC in both B cells and
prostate cancers. We analyzed seven additional independent
microarray datasets (Table 6) where the c-MYC gene was
deregulated and its probe-set signals showed large variance
across samples. In these studies, many predicted MYC targets,
including genes that have been experimentally veriﬁed as
direct MYC targets, failed to show a strong correlation of
target gene expression with MYC expression. The differences
between these datasets cannot be explained by tissue of origin
alone. For example, datasets 2, 3, and 4 are all derived from
the prostate, but the c-MYC correlated targets from these
three datasets do not agree more than those from different
tissues (see Figures S3–S5). Some of this variation could be a
result of technical variation in gene expression proﬁles
between different laboratories and experiments.
This is one of the ﬁrst studies to systematically analyze c-
myc targets in multiple datasets and in multiple tissues; most
previous studies focused on a single tissue or cell line. Our
analysis conﬁrms the well-known ﬁnding that c-MYC is
deregulated in many cancers and has a direct inﬂuence on
the expression of hundreds of other genes. One potential
pitfall in using GO as a criterion for predicting MYC targets is
the possibility of missing important groups of targets that do
not fall into a speciﬁc GO category or are not annotated by
GO at all. In Table S3 we also provide the list of 1,188
predicted targets without applying GO ﬁltering in the
prediction. A second concern is that it is difﬁcult to deﬁne
a test set that is totally independent of prior knowledge
because we cannot exclude the possibility that GO annotators
were aware of MYC regulation status in assigning gene
annotations.
Looking at the target genes we predicted that were not in
the Basso et al. prediction, we ﬁnd variable levels of
correlation with MYC expression across the different datasets
that we have examined. Even genes that have been identiﬁed
as c-MYC targets in published literature often have very
different co-expression patterns with c-MYC in different
microarray datasets. This is consistent with the view that
many of the differences among these high throughput studies
may result from experimental variation, the noise inherent in
these approaches, and the effects of cell density or the
number of culture passages [48]. Whether this reﬂects tissue-
speciﬁc responses or technical variation in microarray data, it
is apparent that a study focusing on any single dataset will be
insufﬁcient. As is shown in Table 6, using multiple datasets
from different studies improved the power of the prediction.
Because the current study only predicted upregulated
genes with MYC binding motifs close to the transcription
start site, which are on the Affymetrix HG-U95Av2 array and
which have GO annotations, we believe that the 460 targets
identiﬁed here underestimate the number of direct MYC
targets in the human genome. Our estimates for the number
of MYC targets in the human genome are roughly consistent
with the MYC database and the high-conﬁdence Zeller [35]
and Cawley [36] studies. They are not inconsistent with the
larger numbers of c-MYC targets suggested by some other
Figure 6. Overlaps of c-MYC Targets Genes
Venn diagrams for the overlap between the set of c-MYC target genes
identified in the different experimental and theoretical studies.
doi:10.1371/journal.pcbi.0030063.g006
Table 7. Comparison of Different MYC Binding Datasets to Genes in MYC Target Database
Dataset Show MYC Regulation
in MYC Target Gene
Database
Show MYC Binding
in MYC Target Gene
Database
Show MYC Regulation
and Binding in MYC
Target Gene Database
Genes in MYC Target Gene Database 495 936 187
460 targets in our prediction 80 68 64
1,188 targets in our prediction (without applying GO filtering) 139 169 82
2,063 genes in the MYC subnetwork predicted in Basso’s paper 156 225 83
668 high-quality MYC direct responsive genes in Zeller’s paper 46 64 26
doi:10.1371/journal.pcbi.0030063.t007
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MYC Response Element Modelstudies [12–15]. One explanation for this range of ﬁndings is
that MYC binding in vivo is not a Boolean event and even
strong MYC binding sites are unlikely to be occupied with
unit stoichiometry. Thus, different studies may be applying
different thresholds for deﬁning a MYC target.
Materials and Methods
Data sources. All the genes in the paper and their Entrez Gene IDs
can be found in Tables S1 and S3.
The HG17 build of the human genome sequence was downloaded
from the University of California Santa Cruz (UCSC) genome
database. The transcription start sites were from the annotated
transcription starts of RefSeq genes in the UCSC genome database
(http://hgdownload.cse.ucsc.edu/goldenPath/hg17/bigZips/
upstream1000.zip). PhastCons scores for multiple alignments of seven
assemblies to the human genome hg17 were downloaded from http://
hgdownload.cse.ucsc.edu/goldenPath/hg17/phastCons/
mzPt1Mm5Rn3Cf1Gg2Fr1Dr1/. The human gene annotation infor-
mation was downloaded from ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/
gene2refseq.gz, and the GO information was downloaded from ftp://
ftp.ncbi.nlm.nih.gov/gene/DATA/gene2go.gz.
Known MYC target genes in previous literature were obtained
from the MYC Target Gene Database [17] (http://www.
myc-cancer-gene.org). The large-scale assay for genomic MYC bind-
ing sites in live human cells was obtained from the supplementary
data of Fernandez et al. [19]. Chromatin acetylation data were
obtained from the supplementary data of Roh et al. [33]. MYC
binding loci on Chromosomes 21 and 22 [36] were downloaded from
http://transcriptome.affymetrix.com/publication/tfbs/, and MYC bind-
ing data in human B cells using ChIP–PET were obtained from the
supplementary data of Zeller et al. [35]. The CREB genomic binding
loci [26] was downloaded from http://natural.salk.edu/CREB. Two
microarray gene expression datasets were used in this study, the B cell
dataset [14] (GSE2350) and the prostate cancer dataset [37] (http://
www.broad.mit.edu/cgi-bin/cancer/datasets.cgi). The B cell dataset
contains 336 samples of normal and transformed human B cells,
and the prostate dataset contains 52 tumor and 50 nontumor
prostate samples. The sources of other microarray gene expression
proﬁle datasets are listed in Table 6.
Construction of the Bayesian network. Bayesian network classi-
ﬁcation was performed using Weka 3.4.5 [34], which is available for
download at http://www.cs.waikato.ac.nz/ml/weka/. When learning the
Bayesian network, the best performance was obtained when using K2
as the search algorithm for local score metrics and using Simple
Estimator with alpha at 0.5 to ﬁnd the conditional probability tables. In
addition, an empty network is set as the initial structure when
learning the network.
The training data contained 43 high-occupancy sites and 90 low-
occupancy sites from Fernandez’s dataset [19]. These sites and their
ChIP primers were mapped back to human genome using the UCSC
In-Silico PCR tool. The ﬁve attributes for every site were derived from
the genome sequence and annotations, including: distance to tran-
scription start site, distance to nearest CpG island, distance to nearest
hypomethylation region, nearest hypomethylation region score, and
phastCons scores [32]. The CpG islands and hypomethylation status
of sequence were predicted as described below. The distances in base
pairs and the hypomethylation scores were transformed to natural
log scale.
Prediction of CpG islands and hypomethylation regions. CpG
islands were predicted by the criteria of Gardiner-Garden [49].
Hypomethylation regions were predicted using a ﬁfth-order Markov
model likelihood ratio test.
Lnm ¼ P
m 5
i¼n
fðsiþ5jsi::siþ4Þ
gðsiþ5jsi::siþ4Þ
where Lnm is the likelihood ratio score that the hexamers in the
interval from n to m are drawn from the frequency distribution for a
training set of hypomethylated sequences relative to the likelihood
that they are drawn from a frequency distribution describing the
genome as a whole. si is the residue occurring at position i in the
sequence, f(siþ5 j si...siþ4) is the frequency of ﬁnding residue siþ5 given
the preceding ﬁve residues si...siþ4 in the hypomethylated DNA
collection, and g(siþ5 j si...siþ4) is the corresponding frequency in the
genome as a whole. The hypomethylation score for a region is the
sum of the log likelihood ratio scores for all overlapping hexamers
in the region, expressed as log base 2. This score measures how
similar the hexamer content of a region is to the hexamer
frequencies in the hypomethylated sequences training set described
below. The boundaries for a predicted hypomethylation region are
chosen to maximize this log likelihood ratio score, with constraints
that each predicted region must score at least 23.1 bits and must not
contain any subregion whose score is more negative than  14.5 bits.
An optimized hexamer score cutoff is determined as shown in
Figure S1.
This algorithm is implemented in the program FMA, a Cþþ
program, which utilizes a hexamer model to predict hypomethylation
regions. The output includes the exact locations of CpG islands, the
fraction of CpG dinucleotides, and the exact location and score
(log2Lnm) of each hypomethylation region. FMA also implements an
efﬁcient indexed motif search. In the ﬁrst phase of the FMA search,
each PSWM in the query set is analyzed and the most informative
contiguous six-nucleotide core segment is identiﬁed. Next, a branch-
and-bound strategy is used to enumerate all hexamers matching this
core segment and able to be extended over the full PSWM to achieve
a speciﬁed log likelihood threshold for the full match. Hexamers in
this set are stored in a sufﬁx tree. During the search, the target
sequence is ﬁrst scanned using the sufﬁx tree to ﬁnd core segment
matches. These matches are then extended over the full PSWM to see
if they achieve the speciﬁed log likelihood threshold. Using this
approach, we are able to exhaustively search large target sequence
libraries for matches to large query sets of PSWM.
The training data for hypomethylated human genomic sequences
were obtained by aligning the hypomethylated sequence tags
collected by Cross et al. [50,51] with the human genome sequence
and extending to the nearest MseI site. These hypomethylated
sequence tag sequences were obtained by digesting human genomic
DNA from peripheral blood leukocytes with MseI, selecting fragments
that failed to bind a methyl–CpG binding protein column, methylat-
ing these fragments in vitro, and subsequently selecting fragments
that bound the methyl–CpG binding protein column. This yields a
collection of genomic DNA fragments that were not methylated in
vivo, but which contained a CpG dinucleotide that could be
methylated in vitro. These fragments were subsequently cloned and
subjected to end-sequence analysis. By aligning the end-sequence tag
to genomic sequence and extending to the nearest MseI site, we
reconstruct the sequence of the full hypomethylated DNA segment.
Validation data for hypomethylation predictions were obtained
from the Human EpiGenome Project [27].
Genome-wide prediction of high-occupancy MYC binding sites.
TRANSFAC was used to scan the human genome sequence for
putative c-MYC binding sites with the MYC–MAX position weight
matrix [MA0059] [29] from the JASPAR database [30].
The sequence attributes for each putative binding site were
inputted into the Bayesian network classiﬁer (see above) to predict
the probability of MYC binding for each site. A site assigned a MYC
binding probability above 0.5 was considered to be a high-occupancy
site. Because almost all the sites in the training data were within 63
Kb of transcription start sites, we limited the prediction of high-
occupancy binding sites to this region for further studies.
The prediction of c-MYC binding genes was based on the high-
occupancy c-MYC binding sites prediction. If a gene contained any
high-occupancy binding site, it was considered a potential c-MYC
binding gene.
Gene expression analysis. The HG-U95Av2 platform annotation
ﬁle was downloaded from Affymetrix. The raw data ﬁles for each
dataset were ﬁrstly normalized with RMA in Bioconductor [38]. For
each probe set, the signal variance across the samples was calculated.
Only probe sets with a signal variance larger than the mean of all
probe sets’ variances were used in co-expression analysis. The
Pearson’s correlation coefﬁcient r was then calculated for every pair
consisting of a c-MYC probe set and another probe set. The
signiﬁcance (probability) of the correlation coefﬁcient is determined
using the t-statistic:
t ¼ r  
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n   2
1   r2
r
where r is the correlation coefﬁcient and n is the sample size. The p-
values from this multiple testing were adjusted to control the false
discovery rate of Benjamini and Hochberg [52]. Only probe set pairs
with an adjusted p-value less than 0.01 were considered to be
signiﬁcantly co-expressed. For a gene to be correlated with c-MYC
expression, it must have at least one probe set with p-value less than
0.01 for both c-MYC probe sets ‘‘1973 s at’’ and ‘‘37724 at.’’
Gene function analysis. We analyzed genes on the HG-U95Av2
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MYC Response Element ModelGeneChip. From the Myc Target Gene Database [17], we extracted the
subset of these genes that were reported to be both bound and
regulated by myc. For these genes, we collected the associated GO
terms from the Molecular Function and Biological Process trees and tested
for signiﬁcant overrepresentation using a hypergeometric test
implemented in the GOHyperG function Bioconductor [38] package
GOstats. A GO term is claimed to be signiﬁcant if the p-value is less
than 0.025.
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